Multiple Myeloma: all 3,713 studies
Page 17 of 38. Open to participants first (754), then studies with results posted, then the rest; newest registration first within each.
- Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00128921Phase 2Results posted
- S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00124579Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantActive, not recruitingNCT00114101Phase 3Results posted
- UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma PatientsTerminatedNCT00113919Phase 1/2Results posted
- Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple MyelomaCompletedNCT00113841Not applicableResults posted
- Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))CompletedNCT00111813Phase 1Results posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesCompletedNCT00104650Phase 2Results posted
- A Multiple Myeloma Trial in Patients With Bone MetastasesCompletedNCT00104104Phase 4Results posted
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsCompletedNCT00103662Phase 3Results posted
- Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple MyelomaCompletedNCT00103506Phase 3Results posted
- Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering MyelomaCompletedNCT00099047Phase 2Results posted
- A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00097981Phase 3Results posted
- Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
- CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00091260Phase 2Results posted
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedNCT00090493Phase 2/3Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple MyelomaCompletedNCT00084747Phase 1/2Results posted
- DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE ConsolidationCompletedNCT00083915Phase 3Results posted
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyCompletedNCT00083551Phase 3Results posted
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideCompletedNCT00083382Phase 2Results posted
- UARK 2003-33, Total Therapy IIICompletedNCT00081939Phase 2Results posted
- Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00075881Phase 2Results posted
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)CompletedNCT00075829Phase 3Results posted
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) AmyloidosisTerminatedNCT00075608Phase 2Results posted
- Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
- Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell TransplantCompletedNCT00068718Phase 1/2Results posted
- S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisCompletedNCT00064337Phase 2Results posted
- S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00064038Phase 3Results posted
- CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00056160Phase 3Results posted
- Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00054353Phase 1/2Results posted
- NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple MyelomaCompletedNCT00049673Phase 3Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00040937Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
- Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple MyelomaCompletedNCT00006244Phase 2Results posted
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedNCT00006184Phase 2Results posted
- Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaCompletedNCT00004088Phase 2Results posted
- Antineoplaston Therapy in Treating Patients With Multiple MyelomaTerminatedNCT00003511Phase 2Results posted
- Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
- Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving ChemotherapyCompletedNCT00002850Phase 3Results posted
- Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic LeukemiaCompletedNCT07882069Not applicable
- A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In GreeceActive, not recruitingNCT07814170Not applicable
- CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07809594Phase 1
- Individualized Education for Bortezomib-Related Symptom Management in Multiple MyelomaCompletedNCT07774988Not applicable
- Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide RegimensCompletedNCT07689006
- Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral NeuropathyCompletedNCT07614243Not applicable
- EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer PatientsCompletedNCT07457112Not applicable
- A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)WithdrawnNCT07428369Phase 2/3
- A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in TaiwanActive, not recruitingNCT07391761
- Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic AnemiaCompletedNCT07354191Not applicable
- A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07342114Phase 1
- CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple MyelomaSuspendedNCT07340853Phase 1
- Study of BMS-986453 in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT07333261Phase 1
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT07266441Phase 2
- Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above TreatmentWithdrawnNCT07195617Not applicable
- Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)Active, not recruitingNCT07154537Phase 4
- Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West BankCompletedNCT07152938Not applicable
- Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T CellsCompletedNCT07150468
- Phase I Trial of GR1803 Injection in Patients With RRMMCompletedNCT07102706Phase 1/2
- Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)SuspendedNCT07102212Not applicable
- The Effect of Mobile Application-Based Education Developed According to Orem's Self-Care Model in Multiple Myeloma PatientsCompletedNCT07088783Not applicable
- Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple MyelomaWithdrawnNCT07082270Phase 1
- Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T CellsWithdrawnNCT07071909Phase 1/2
- Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaTerminatedNCT07045727Not applicable
- A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruitingNCT07030517Phase 4
- Feasibility, Safety and Effectivity of an Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients During Induction TherapyActive, not recruitingNCT07026799Not applicable
- A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaActive, not recruitingNCT06952478Phase 3
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Phase 1
- Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06924424Not applicable
- Implementing a Randomized Control Trial to Test the Expanded Web-based Decision AidActive, not recruitingNCT06910670Not applicable
- Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaSuspendedNCT06876142Phase 1/2
- Rehabilitation Management for Patients With Multiple MyelomaCompletedNCT06838065
- UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT06698744Phase 1
- A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.SuspendedNCT06691685Early Phase 1
- Melflufen for Elderly Patients With Relapsed MyelomaWithdrawnNCT06682637Phase 2
- Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaSuspendedNCT06663046Early Phase 1
- 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
- The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World StudyCompletedNCT06610045
- A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06604715Phase 1
- A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesCompletedNCT06592222
- ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple MyelomaTerminatedNCT06588660Phase 1
- Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).Active, not recruitingNCT06581848
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06577025Phase 2
- External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary DiseaseSuspendedNCT06572605Phase 1/2
- GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06566547Phase 2
- A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell TransplantCompletedNCT06559709Not applicable
- Finistere Myeloma Observatory (OMYFIN)CompletedNCT06552221
- A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruitingNCT06550895Phase 2
- Biomarkers of AKI in Patients Receiving DaratumumabCompletedNCT06549634
- A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF MobilizationCompletedNCT06547112Phase 1
- Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantActive, not recruitingNCT06523699Phase 1
- Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelActive, not recruitingNCT06523621Phase 2
- Novel Treatments in Improving Renal Outcomes in Light Chain Cast NephropathyCompletedNCT06483139